lunedì, 30 novembre 2020
27 Aprile 2018

FDA Grants Fast Track Designation for Balixafortide in Combination With Eribulin as Third-Line Therapy for Metastatic Breast Cancer

April 24, 2018 – On April 19, Polyphor announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its novel immuno-oncology candidate balixafortide (POL6326) in combination with eribulin for the treatment of patients with HER2-negative metastatic breast cancer who previously received at least two chemotherapeutic regimens in the metastatic setting. Balixafortide is a potent and highly selective antagonist of CXCR4, a G-protein coupled … (leggi tutto)